From research to patient, from incubation to technology transfer: The first integrated Antibody-Drug Conjugates (ADC) HUB in Italy
THE PROJECT IS OFFICIALLY LAUNCHED
Contact us
Nexantia Biotherapeutics was founded with a clear mission: to position Italy as a European hub for Antibody–Drug Conjugates (ADCs), with a strategic network of connection with some of the most important research centers in US. We bring together within a single ecosystem what is usually fragmented: Cutting-edge research, GMP-certified manufacturing, advanced training, and the acceleration of new biotech ventures.
Why ADCs. Why Now.
ADCs are opening a new chapter in oncology therapy — one of the most promising frontiers in modern medicine. Europe is entering a new phase, one in which ADC research, GMP biomanufacturing, and biotech training converge within a single hub. Nexantia Project was created to lead this transformation. We are not just developing therapies — we are building bridges:
• Between science and patients
• Between talent and opportunity
• Between innovation and society
Proprietary oncology ADC pipeline advancing to Phase I, ready for licensing.
A global connection with the best CDMOs, GMP-certified for manufacturing and technology transfer capabilities.
Developing biotech talent with next-generation tools, including VR/MR throughout Biotech Academy in Rome, a training division of Nexantia Biotherapeutics.
Supporting Italian and international start-ups, from idea to market entry.
Our goal is to accelerate the journey of innovation from the laboratory to the patient — advancing oncology research and creating long-term value for society.
30+ years of experience. Strategic leadership, new technology development, GMP process implementation, with focus on international projects in healthcare and biopharmaceuticals. Former Executive Director of MOOKP Medical Research Foundation (US and Latam branch), and Institute of Advanced Ocular Surgery and Applied Neurosciences (Chile).
20+ years of experience. Process development and GMP manufacturing of clinical grade drug substances, and coordination of international R&D project. Former Head of Process Development at Menarini Biotech, Head of Large-Scale GMP Manufacturing at ReiThera.
Extensive experience in business and tax consulting, budget preparation, tax law, and financial analysis. Certified Italian Advisor at the Italian Chamber of Commerce Abroad and member of the Collegio Sindacale of UNICEF Italy. Chartered Accountant and Statutory Auditor at Studio TEATINI, member of the Equal Opportunities Committee of ODCEC Rome, and Treasurer of Fiaba ETS.
25+ years of experience in education and training within chemistry and biotechnology. School teacher of Chemistry and Biotechnology at the Institute Interstudio. Director and Owner of Istituto Studi Atena, a specialized facility providing cleanroom and sterile environment training courses.
Over 20 years of international experience in Marketing, Sales, and Strategic Growth. Specialized in brand strategy, business development, and cross-cultural leadership. Former Director of Sales & Marketing at Marriott International (Caribbean & LatAm) and Starwood Hotels & Resorts. Currently Director of Marketing & Communications at BetaPro Consulting.
40+ years experience. Pioneer in ADCs clinical and commercial development with over 150 scientific publications and more than 40 issued patents. Former in international institutions (Bristol-Mayers Squibb, Dana-Farber Cancer Istitute, Harvard Medical School).
25+ years of experience. Highly distinguished physician scientist and leading expert in the field of pediatric acute myeloid leukemia (AML). Globally recognized expertise in large-scale multi-omic studies(1) conducted on thousands of pediatric and young adult patients. Professor of Pediatrics at the University of Washington School of Medicine.
40+ years experience. Background in immunology, oncology, and translational medicine with a focus on personalized cancer care. Author of 150+ peer-reviewed publications and leading voice in cancer immunology and personalized medicine. Former Vice-Director of the Immunology Laboratory and Head of Clinical Trial Center at IRCCS National Cancer Institute Regina Elena.
38+ years experience. Expertise in gynecology and obstetrics, with a focus on oncology and cancer clinical care. Co-founder of U3 Pharma in Martinsried, Germany, a biotech venture that contributed to early development of ADCs cancer therapies. Former Director of the Cancer Clinic at University Hospital SS. Annunziata in Chieti and President of the Mediterranean Task-Force for Cancer Control.
Medical Doctor specialized in Oncology, with advanced training in Clinical Oncologic Hyperthermia. Head of General Medicine at Clinica Fabia Mater (Rome) and Oncology Specialist at Clinica Ars Biomedica. Member of ASCO, SIO, ESHO, and founding member of ARTOI, author of several works on integrative and personalized cancer therapy.
Our mission is to generate lasting impact across the global biotech and pharmaceutical ecosystem:
Human Capital: Preparing the next generation of biotech leaders.
Industrial Innovation: Boosting competitiveness in Italy and Europe, while fostering global integration through cross-border collaboration, technology transfer, and industrial scale-up.
Technological Leadership: Strengthening Italy’s role as a leader in oncology innovation.
Nexantia offers a unique and solid foundation for growth:
A fully controlled supply chain.
An ADC oncology pipeline with validated targets.
A diversified model combining R&D, services, training, and incubation.
Strong alignment with Italian, European and US institutions.
Let’s Build the Future Together.
We collaborate with institutions, investors, and innovators who share our vision.
Reach out to explore opportunities, partnerships, and projects that will shape
the next generation of ADC.
+39 331 809 6574
Viale di Trastevere, 141 – 00153 (RM) Rome - Italy
P.IVA/C.F.: IT17204271005
SDI: 5RUO82D